Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine

PLoS One. 2015 Jul 20;10(7):e0133126. doi: 10.1371/journal.pone.0133126. eCollection 2015.

Abstract

Carrier-specific T cell and polysaccharide-specific B cell memory responses are not well characterised in infants following glyco-conjugate vaccination. We aimed to determine if the number of Meningococcal (Men) C- and Y- specific memory B cells and; number and quality of Tetanus Toxoid (TT) carrier-specific memory CD4+ T cells are associated with polysaccharide-specific IgG post HibMenCY-TT vaccination. Healthy infants received HibMenCY-TT vaccine at 2, 4 and 6 months with a booster at 12 months. Peripheral blood mononuclear cells were isolated and polysaccharide-specific memory B cells enumerated using ELISpot. TT-specific memory CD4+ T cells were detected and phenotyped based on CD154 expression and intracellular TNF-α, IL-2 and IFN-γ expression following stimulation. Functional polysaccharide-specific IgG titres were measured using the serum bactericidal activity (SBA) assay. Polysaccharide-specific Men C- but not Men Y- specific memory B cell frequencies pre-boost (12 months) were significantly associated with post-boost (13 months) SBA titres. Regression analysis showed no association between memory B cell frequencies post-priming (at 6 or 7 months) and SBA at 12 months or 13 months. TT-specific CD4+ T cells were detected at frequencies between 0.001 and 0.112 as a percentage of CD3+ T cells, but their numbers were not associated with SBA titres. There were significant negative associations between SBA titres at M13 and cytokine expression at M7 and M12.

Conclusion: Induction of persistent polysaccharide-specific memory B cells prior to boosting is an important determinant of secondary IgG responses in infants. However, polysaccharide-specific functional IgG responses appear to be independent of the number and quality of circulating carrier-specific CD4+ T cells after priming.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial / blood
  • Antibodies, Bacterial / immunology
  • B-Lymphocytes / cytology
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism*
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism*
  • CD40 Ligand / metabolism
  • Cells, Cultured
  • Female
  • Haemophilus Vaccines / immunology*
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Infant
  • Interferon-gamma / metabolism
  • Interleukin-2 / metabolism
  • Leukocytes, Mononuclear / cytology
  • Male
  • Meningitis, Meningococcal / immunology
  • Meningitis, Meningococcal / prevention & control
  • Tetanus Toxoid / immunology*
  • Tumor Necrosis Factor-alpha / metabolism
  • Vaccines, Conjugate / immunology

Substances

  • Antibodies, Bacterial
  • Haemophilus Vaccines
  • Hib-MenCY-TT vaccine
  • Immunoglobulin G
  • Interleukin-2
  • Tetanus Toxoid
  • Tumor Necrosis Factor-alpha
  • Vaccines, Conjugate
  • CD40 Ligand
  • Interferon-gamma

Grants and funding

This research was funded by the National Health and Medical Research Council (AJC and PCR; http://www.nhmrc.gov.au). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.